Biocon share news, announcements and annual reports
NSE: BIOCONBSE: 532523Pharmaceuticals & BiotechnologyMid Cap
Biocon Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2004
Last close ₹351.80down ₹0.10 (0.03%)BSE ₹352.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹351.90.
30 Oct: open ₹352.70, high ₹355.50, low ₹348.70
52-week range of traded prices to 30 Oct 2026
₹318.40Low, 23 Oct 2026₹447.15High, 16 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹57,333 Cr173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 115.75
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 64.09
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.68
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.14%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 20,63,63747.1% delivered
Biocon share news and announcements
1,771 announcements, routine notices left out, newest first. Page 32 of 36.
Oct 2012
31 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2012 as follows: Net Sales of Rs. 59240 lacs for the quarter ending on 30-SEP-2012 against Rs. 57086 lacs and Rs. 50844 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively. Net Profit / (Loss) of Rs. 8965 lacs for the quarter ending on 30-SEP-2012 against Rs. 7880 lacs and Rs. 8570 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively.31 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2012 as follows: Net Sales of Rs. 46140 lacs for the quarter ending on 30-SEP-2012 against Rs. 43160 lacs and Rs. 37849 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively. Net Profit / (Loss) of Rs. 8836 lacs for the quarter ending on 30-SEP-2012 against Rs. 6884 lacs and Rs. 6807 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively.15 Oct · Board meeting
Inter alia, to : (1) Approve and take on record the unaudited financial results of the Company for the quarter and half year ended on September 30, 2012.
Sep 2012
Jul 2012
27 Jul · Dividend
Final dividend of Rs. 5.00 per equity share declared by the members of the Company at the Annual General Meeting held on July 26, 2012 will be paid out on July 31, 2012.26 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 57086 lacs for quarter ending on 30-JUN-2012 against Rs. 44168 lacs for the quarter ending on 30-JUN-2011. Net Profit / (Loss) of Rs. 7880 lacs for the quarter ending on 30-JUN-2012 against Rs. 7005 lacs for the quarter ending on 30-JUN-2011.26 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 43160 lacs for quarter ending on 30-JUN-2012 against Rs. 33890 lacs for the quarter ending on 30-JUN-2011. Net Profit / (Loss) of Rs. 6884 lacs for the quarter ending on 30-JUN-2012 against Rs. 6040 lacs for the quarter ending on 30-JUN-2011.16 Jul · Board meeting
Inter alia to : (a) Approve and take on record the unaudited financial results of the Company for the quarter ended on June 30, 2012; (b) Consider merger of Biocon Biopharmaceuticals Limited, a wholly owned subsidiary with the Company.
Jun 2012
26 Jun · Meeting
Company has announced the Book Closure from July 07, 2012 to July 21, 2012 (both days inclusive) for the purpose of Annual General Meeting and Final Dividend. Further, the Annual General Meeting will be held on July 26, 2012.
May 2012
26 May · Demise of Director
It is with deep sadness that Biocon announces that demise of Dr. Neville Bain, Non-Executive Director and Chairman of the Audit Committee on May 22nd, 2012 at his home in London. Dr. Bain Joined the Board of Biocon Limited in 1999 and has contributed substantially to building high standards of Governance in Biocon's Financial Reporting and Risk Management Systems. Biocon Pays homage to a Director who carried out his fiduciary duties in an impeccable manner. We offer our heartfelt condolences to his wife and family. May his soul rest in peace
Apr 2012
27 Apr · Dividend
Board of Directors of the Company at its meeting held on April 27, 2012 have recommended a final dividend of 100% (Rs 5.00 per share) on the share capital of the Company, subject to the approval of the members at the ensuing Annual General Meeting.17 Apr · Board meeting
Inter alia, to approve and take on record the audited financial results of the Company for the year ended on March 31, 2012 and to consider recommendation of payment of dividend, if any, for the year 2011-2012.
Mar 2012
Jan 2012
5 Jan · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on December 31, 2011.
Dec 2011
Oct 2011
20 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2011 as follows: Net Sales of Rs. 37849 lacs for quarter ending on 30-SEP-2011 against Rs. 33612 lacs for the quarter ending on 30-SEP-2010. Net Profit / (Loss) of Rs. 6807 lacs for the quarter ending on 30-SEP-2011 against Rs. 8733 lacs for the quarter ending on 30-SEP-2010.20 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2011 as follows: Net Sales of Rs. 50844 lacs for quarter ending on 30-SEP-2011 against Rs. 67877 lacs for the quarter ending on 30-SEP-2010. Net Profit / (Loss) of Rs. 8570 lacs for the quarter ending on 30-SEP-2011 against Rs. 8922 lacs for the quarter ending on 30-SEP-2010.17 Oct · Board meeting
Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on October 20, 2011 inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on September 30, 2011. The Company has now informed the Exchange that the aforesaid Board Meeting has been preponed and will now be held on October 19, 2011.Not held on this date
11 Oct · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on September 30, 2011.
Sep 2011
Aug 2011
Jul 2011
22 Jul · Meeting
22 Jul · Dividend
Final dividend of Rs.3.00 per equity share declared by the members of the Company at the Annual General Meeting held on July 21, 2011 will be paid out on July 27, 2011.